Actusnews Wire - Professional broadcaster of corporate and regulated information, authorised by the AMF and the CSSF.

  DMS company press release from 22/05/2018

  22/05/2018 - 18:00

Further progress for the DMS Biotech division: finalization of a pre-clinical study on the treatment of erectile dysfunctions


Diagnostic Medical Systems Group (Euronext Paris - FR0012202497 - DGM) announces the finalization of a study carried out on rats- for the treatment of erectile dysfunctions; The study was conducted in collaboration with the company Urosphere, specialized in urology pre-clinical studies.

This study showed, in rats with surgically triggered erectile dysfunctions, that the treatment with a cellular solution purified from adipose tissue leads to the recovery of erections in over 50% of the treated rats. Moreover, the erections efficiency is similar to what was observed in control rats.

The cells were purified with an innovative device, recently patented by DMS Biotech, allowing cellular populations specific to the adipose tissue to be extracted in just a few minutes, whereas classical extraction processes usually require 1 to 3 hours.

In addition to the quick procedure, the study also shows that the new device developed by DMS Biotech obtains a cellular preparation that restores a better-quality erection, when compared with the classical extraction processes.

The results we obtained are extremely positive because we can see a fast regrowth of the cavernous nerves damaged during surgery. It is essentially this regenerative action that leads to treatment efficiency. The mechanism still has to be proven in men but these results on the small animal go beyond our expectations.” explains Régis Roche, Scientific Manager of DMS Biotech.

“It is more than encouraging for the future of these treatments. t Prostate ablation as part of cancer treatment leads, most of the time, to erectile dysfunctions, very often irreversible. In these situations, the classical medicinal treatments (Viagra, Cialis, etc.) are not efficient and the solution of penile implant is complicated and difficult to consider. A solution by local unique-injection of an autologous cellular preparation is extremely tempting and could radically change the lives of tens of millions of patients in the world.”

 


About DMS Group
DMS Group
is composed of companies with a high innovation potential. First focused on medical imaging industry, it now grows to new horizons. Investing in the future and in research, DMS Group aims to bring tomorrow's solutions.

  • Specialized in high-technology for medical diagnosis, DMS Imaging is now the French leader in development, design and manufacture of medical imaging dedicated to radiology, bone densitometry, 3D modelling and posturology.

  • DMS Wellness gathers the activities dedicated to health and wellness, aimed at specialists of physiotherapy, beauty, esthetics and sport.

  • DMS Biotech accompanies the development strategy of the group in the area of biotechnologies, and more specifically technologies for the treatment of arthritis and regenerative medicine based on the injection of adipose stem cells.

DMS Group is present on every continent through a network of over 140 national distributors, branches and joint-ventures.
In 2017, DMS Group reached a consolidated turnover of 27,1 M€. DMS Group is listed on Euronext Paris Exchange (ISIN: FR0012202497 - mnémo: DGM).

More information on www.dms.com


SUBSCRIBE FOR FREE TO DMS GROUP FINANCIAL INFORMATION AT WWW.ACTUSNEWS.COM


Contacts :

DMS Group
Jean-Paul ANSEL
CEO
+33 (0)4 67 50 49 00
ACTUS FINANCE
Mathieu OMNES
Investors Relations
+33 (0)1 53 67 36 92
ACTUS FINANCE
Alexandra PRISA
Press Relations
+33 (0)1 53 67 36 90